ECE2010 Poster Presentations Clinical case reports and clinical practice (80 abstracts)
Macroprolactinoma after chronic buserelin treatment in patient with prostate cancer
Ferenc A Laszlo 1 , Mihály Gervain 2 , Erika Voros 3 , Andor H Molnár 1 & Ferenc Laszlo 1
1Department of Physiology, Anatomy and Neurosciences, University of Szeged, Szeged, Hungary; 2Department of Urology, City Hospital, Orosháza, Hungary; 3Department of Radiology, University of Szeged, Szeged, Hungary.
Twelve years following hemicolectomy for colon adenocarcinoma, a 75-year-old patient with prostate cancer was treated for 4 weeks with the antiandrogen nilutamide and then with the long-acting GnRH agonist buserelin. The serum testosterone and prostate-specific antigen (PSA) levels had decreased dramatically after 3 months of treatment. After 2 years of buserelin administration, the hormonal state was examined. Serum estradiol, testosterone, DHEA, DHEAS, FSH and LH levels proved to be suppressed, but the serum PRL concentration was extremely high (3 365 mIU/l). The pituitary MRI revealed a macroadenoma. The patient was treated with the dopamine agonist cabergoline, together with buserelin. After 5 months of this combined treatment, the PSA and testosterone levels were very low; the serum oestradiol, DHEA, DHEAS, FSH and LH concentrations remained suppressed. The serum PRL level fell dramatically to 6.95 mIU/l, and a reduction in tumor size was observed on MRI. In conclusion: Combined buserelin + cabergoline treatment proved a highly successful procedure to cure this patient with prostate carcinoma and subsequent pituitary macroprolactinoma.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more